GSA Capital Partners LLP Buys New Shares in Invivyd, Inc. $IVVD

GSA Capital Partners LLP bought a new position in shares of Invivyd, Inc. (NASDAQ:IVVD) in the 2nd quarter, according to its most recent Form 13F filing with the SEC. The fund bought 662,065 shares of the company’s stock, valued at approximately $578,000.

Other large investors also recently bought and sold shares of the company. Chicago Partners Investment Group LLC acquired a new stake in Invivyd in the 1st quarter valued at about $25,000. Courier Capital LLC acquired a new position in shares of Invivyd during the fourth quarter worth about $25,000. Bronte Capital Management Pty Ltd. purchased a new stake in shares of Invivyd during the fourth quarter worth approximately $27,000. DRW Securities LLC purchased a new stake in shares of Invivyd during the fourth quarter worth approximately $27,000. Finally, ProShare Advisors LLC purchased a new stake in shares of Invivyd during the fourth quarter worth approximately $30,000. Hedge funds and other institutional investors own 70.36% of the company’s stock.

Invivyd Price Performance

Shares of IVVD opened at $0.95 on Friday. Invivyd, Inc. has a 1-year low of $0.48 and a 1-year high of $3.07. The stock has a market cap of $280.26 million, a PE ratio of -2.88 and a beta of 0.71. The firm has a fifty day moving average price of $0.78 and a 200 day moving average price of $1.22.

Invivyd (NASDAQ:IVVD) last issued its quarterly earnings data on Thursday, August 13th. The company reported ($0.14) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.11) by ($0.03). Invivyd had a negative return on equity of 59.73% and a negative net margin of 183.90%.The firm had revenue of $14.29 million for the quarter, compared to analysts’ expectations of $14.40 million. As a group, equities analysts expect that Invivyd, Inc. will post -0.51 EPS for the current fiscal year.

Analyst Ratings Changes

A number of research analysts recently issued reports on IVVD shares. Weiss Ratings reiterated a “sell (d-)” rating on shares of Invivyd in a research note on Friday, July 24th. Wall Street Zen downgraded shares of Invivyd from a “hold” rating to a “strong sell” rating in a research report on Saturday, May 16th. HC Wainwright restated a “buy” rating on shares of Invivyd in a report on Tuesday. Finally, BTIG Research restated a “buy” rating on shares of Invivyd in a report on Tuesday, July 7th. Three research analysts have rated the stock with a Buy rating, two have given a Hold rating and one has issued a Sell rating to the company’s stock. According to MarketBeat.com, Invivyd has a consensus rating of “Hold” and an average price target of $8.00.

Insider Transactions at Invivyd

In other Invivyd news, insider Jill Andersen sold 37,256 shares of Invivyd stock in a transaction that occurred on Monday, August 17th. The stock was sold at an average price of $0.72, for a total transaction of $26,824.32. Following the transaction, the insider owned 314,480 shares of the company’s stock, valued at $226,425.60. The trade was a 10.59% decrease in their ownership of the stock. The transaction was disclosed in a filing with the SEC, which is available at this hyperlink. The sale was made to cover tax withholding obligations related to the vesting of equity awards. In the last quarter, insiders sold 228,024 shares of company stock worth $176,540. Company insiders own 12.25% of the company’s stock.

About Invivyd

Invivyd, Inc, a commercial-stage biopharmaceutical company, focuses on the discovery, development, and commercialization of antibody-based solutions for infectious diseases in the United States. The company developed INVYMAB, a platform that combines viral surveillance and predictive modeling with advanced antibody engineering. Its pipeline includes PEMGRADA (pemivibart) injection, a half-life extended investigational monoclonal antibody (mAb) for the prevention of COVID-19 in adults and adolescents; VYD2311, an mAb candidate which is in preclinical studies for the prevention or treatment for COVID-19; and adintrvimab, that is in phase 3 clinical trials for the prevention or treatment of COVID-19.